Search results
Showing 91 to 105 of 308 results for eq-5d
Romiplostim for the treatment of chronic immune thrombocytopenia (TA221)
Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune thrombocytopenia in adults.
Long term real-world data is needed on AposHealth's clinical effectiveness and cost benefit
collected using standardised patient-reported outcome measures, such as the EQ-5D. Source guidance details Comes from guidance AposHealth
recommended that data are collected using validated measure(s) of HRQoL, including EQ-5D. Source guidance details Comes from guidance...
Data should be collected using validated measure(s) of HRQoL, including EQ-5D Source guidance details Comes from guidance Sickle cell
Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)
Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.
Idelalisib for treating chronic lymphocytic leukaemia (TA359)
Evidence-based recommendations on idelalisib (Zydelig) for treating chronic lymphocytic leukaemia in adults.
recommended that data are collected using validated measure(s) of HRQoL,including EQ-5D. Source guidance details Comes from guidance...
Evidence-based recommendations on erenumab (Aimovig) for preventing migraine in adults.
Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)
Evidence-based recommendations on obinutuzumab (Gazyvaro) with chlorambucil for untreated chronic lymphocytic leukaemia in adults.
outcome measures) both health-related quality of life (measured using the EQ-5D) and health service resource use, to enable the results...
outcome measures) both health-related quality of life (measured using the EQ-5D) and health service resource use, to enable the results...
Tocilizumab for the treatment of rheumatoid arthritis (TA247)
Evidence-based recommendations on tocilizumab (RoActemra) for treating rheumatoid arthritis in adults.
Evidence-based recommendations on olaparib (Lynparza) for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy in adults.
Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325)
Evidence-based recommendations on nalmefene (Selincro) for reducing alcohol consumption in adults with alcohol dependence.
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma in adults.